BSX - Embedded Expectations Analysis - 2021 09 01
Boston Scientific Corporation (BSX:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 23.6x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may have concerns about their growth, Fast-Acting Sub-perception Therapy (FAST), and the launch of their WaveWriter Alpha SCS system.Specifically, management may lack confidence in their ability to sustain adjusted EPS growth, Asia Pacific and Emerging Markets sales growth, and record drug-eluting portfolio sales within arterial. Moreover, they may have concerns about the launch of their next-gen WaveWriter Alpha SCS system, the efficacy of their Fast-Acting Sub-perception Therapy (FAST), and the potential of their Elegance registry study. Furthermore, management may lack confidence in their ability to meet their operational revenue growth outlook and maintain growth in their deep brain stimulation business. Finally, they may have concerns about the impact of pandemic-related headwinds, particularly in Japan, and they may lack confidence in their ability to gain more market share in the U.S.
Boston Scientific develops, manufactures and markets medical devices. The company's Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. The company's Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.